Jaids-Journal of Acquired Immune Deficiency Syndromes

Papers
(The H4-Index of Jaids-Journal of Acquired Immune Deficiency Syndromes is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
HIV and Aging in the Era of ART and COVID-1979
Addressing Stigma by Increasing Empathy Toward Vulnerable Populations in Preprofessional Trainees: Impacts of the Generation Tomorrow Summer Health Disparities Scholars Program70
Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037)61
Patterns of HIV Treatment Preferences Among People With Diverse Demographic, Social, and Behavioral Characteristics Who Are Living With HIV in the United States47
Trends in the Uptake of Index Testing Among Adolescents in USAID-Supported President's Emergency Plan for AIDS Relief Programs, October 2017–September 202234
Predictors of Injection Visit Adherence in Those Receiving Injectable Cabotegravir/Rilpivirine30
The Strategies Timeline and Activities Reporting Tables: Improving HIV Care by Improving the Reporting of Implementation Strategies29
HIV Testing Among Transgender and Other Gender-Diverse Persons in the United States: A Scoping Review29
Long-acting injectable PrEP can substantially reduce HIV incidence in Los Angeles County: A simulation study27
Supplemental Issue of the Journal of the Acquired Immune Deficiency Syndromes (JAIDS): The Centers for AIDS Research (CFAR) Diversity, Equity, and Inclusion Pathway Initiative (CDEIPI)26
Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study25
Using Data-To-Care Strategies to Optimize the HIV Care Continuum in Connecticut: Results From a Randomized Controlled Trial24
The Cooperative Re-Engagement Controlled Trial (CoRECT): Durable Viral Suppression Assessment23
Clinician Perspectives on Disclosing Public Health Uses of HIV Antiretroviral Resistance Testing Results22
Breastfeeding Among Women Living With HIV in the Era of Lifelong ART: An Observational Multicountry Study in Eastern and Southern Africa22
Understanding Disparities in Antiretroviral Therapy Adherence and Sustained Viral Suppression Among Black, Hispanic/Latina, and White Women in the United States – Medical Monitoring Project, United St22
Brief Report: Clinical Features and Outcomes of mpox in People With and Without HIV: A National Comparative Study21
Prevalence and Risk Factors of Low Bone Mineral Density in HIV/AIDS Patients: A Chinese Cross-Sectional Study21
Brief Report: Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials20
Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial20
0.26504778862